Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Non-Current Liabilities (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $46.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 19.58% year-over-year to $46.3 million, compared with a TTM value of $46.3 million through Sep 2025, down 19.58%, and an annual FY2024 reading of $54.1 million, up 69.05% over the prior year.
  • Total Non-Current Liabilities was $46.3 million for Q3 2025 at Spyre Therapeutics, down from $83.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $432.0 million in Q3 2023 and bottomed at $20.8 million in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $70.8 million, with a median of $35.8 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities surged 1699.08% in 2023, then plummeted 90.13% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $26.0 million in 2021, then dropped by 19.75% to $20.8 million in 2022, then surged by 53.45% to $32.0 million in 2023, then soared by 69.05% to $54.1 million in 2024, then dropped by 14.4% to $46.3 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SYRE at $46.3 million in Q3 2025, $83.1 million in Q2 2025, and $70.7 million in Q1 2025.